Every question we get, answered
The whole program in one page. Each answer links to the deep-dive guide behind it.
Eligibility summary corrected October 6, 2026; other answers were not revised in this correction.
Jump to a question
- What is the Medicare GLP-1 Bridge program?
- Who qualifies for the $50 GLP-1 program?
- How do I apply?
- Is $50 really the whole price?
- I have type 2 diabetes. Am I eligible?
- Which drugs are covered?
- Why was I quoted more than $50 at the pharmacy?
- Does Extra Help / LIS lower the $50?
- Do I need to switch Medicare plans to use the program?
- When does the program end?
- How much weight do people lose on these medications?
- What are the side effects?
- Can my BMI be measured at home for eligibility?
- What counts as prediabetes, and why does everyone mention it?
- My prior authorization was denied. Is that final?
- Does the program work if I spend winters in another state?
- Is there a cheaper way than $50?
- What happens to people mid-treatment when the program ends?
- Is this website affiliated with Medicare or CMS?
What is the Medicare GLP-1 Bridge program?
A temporary CMS demonstration (July 1, 2026 – December 31, 2027) that lets eligible people with Medicare drug coverage fill Wegovy, Zepbound (KwikPen), or Foundayo for a flat $50 a month. It runs nationally, outside your Part D plan, through a central processor administered by Humana. The program explained →
Who qualifies for the $50 GLP-1 program?
You need an eligible Medicare drug-plan type and must meet the adult weight-management and authorization requirements. A GLP-1 paid through Part D in 2026 rules out Bridge access for 2026. The clinical tiers use BMI at therapy initiation: 35+; 30+ with CKD stage 3a+, HFpEF or the specified uncontrolled hypertension; or 27+ with prediabetes, prior heart attack or stroke, or symptomatic PAD. BMI alone does not establish full program eligibility. Full eligibility rules →
How do I apply?
The prescriber sends a prescription to the pharmacy, which submits a Bridge claim first. The initial claim requests PA; then the prescriber submits it. Patients do not submit the authorization themselves. How to apply, step by step →
Is $50 really the whole price?
Yes — $50 per monthly fill, no deductible, same price all year and in every state. The catches are different: the $50 doesn't count toward your Part D out-of-pocket cap, and Extra Help doesn't reduce it. The $50, explained →
I have type 2 diabetes. Am I eligible?
Not for the Bridge — but that's usually good news: Medicare already covers GLP-1s like Ozempic and Mounjaro for diabetes under standard Part D, where Extra Help applies and payments count toward the annual cap. Sleep apnea (moderate-to-severe) and MASH route the same way under their own indications. The diabetes path →
Which drugs are covered?
Three: Wegovy, Zepbound — in KwikPen form only, a rule that catches many people at the pharmacy — and Foundayo. All three cost the same $50 per monthly fill. The covered drugs →
Why was I quoted more than $50 at the pharmacy?
Ask the pharmacist which processor and formulation are being billed, whether PA is required or approved, and what the exact claim response says. Do not assume that a price difference has only one cause. Pharmacy troubleshooting →
Does Extra Help / LIS lower the $50?
No. The program sits outside Part D, where Extra Help operates, so everyone pays the same $50. If you have Extra Help and a routing condition like diabetes, the standard Part D path may cost you less. The Extra Help catch →
Do I need to switch Medicare plans to use the program?
No — the Bridge works identically alongside eligible Part D plan types, with no plan opt-in. CMS excludes certain plan types unless a separate standalone PDP applies. Confirm your plan type before changing coverage. MA vs. PDP details →
When does the program end?
December 31, 2027, with no announced extension or successor. Check the dated official guidance and discuss continuation with your prescriber. Extension tracker →
How much weight do people lose on these medications?
Results depend on the specific formulation, dose, population and treatment plan. Ask your prescriber about the relevant evidence and your own goals; coverage does not predict your weight loss. The honest comparison →
What are the side effects?
Mostly gastrointestinal — nausea, constipation, diarrhea — concentrated during dose increases and typically improving with time. The labels also include serious warnings, contraindications and interactions; discuss the complete label and concerning symptoms with your prescriber. Drug guides with dosing detail →
Can my BMI be measured at home for eligibility?
Use the BMI from when GLP-1 therapy started, even before Medicare enrollment or July 2026. If you have already lost weight, ask your prescriber for the starting records. The calculator is an estimate: it rounds to one decimal, to match the one-decimal BMI ranges on the CMS prior-authorization form, and uses that number for the thresholds. If you are right at a threshold, confirm it against your prescriber's records. Run the eligibility check →
What counts as prediabetes, and why does everyone mention it?
CMS lists clinician-confirmed prediabetes as a qualifying condition at starting BMI 27 or higher. Ask your prescriber to review the diagnosis and other criteria; this guide does not establish diagnosis from a single test. The prediabetes path →
My prior authorization was denied. Is that final?
Check the exact reason. A first pharmacy rejection requesting PA is expected. CMS has no Bridge appeals process, but the prescriber may resubmit corrected, updated or additional information. Approval is not guaranteed. What to do after a denial →
Does the program work if I spend winters in another state?
Yes — it's one of the most portable benefits in Medicare. The program runs nationally through one processor, so any participating pharmacy in any state fills at the same $50. The snowbird guide →
Is there a cheaper way than $50?
Within the Bridge, the copay is fixed. Compare actual eligible quotes and fees. Other routes can include the standard Part D route with Extra Help (if a routing condition applies to you), or state Medicaid coverage for some dual-eligibles. Every cost comparison →
What happens to people mid-treatment when the program ends?
Unless CMS acts, fills after December 31, 2027 fall to other coverage or self-pay — so the exit-strategy conversation with your prescriber matters. Some patients will have developed routing diagnoses by then and move to Part D coverage. Planning for 2028 →
Is this website affiliated with Medicare or CMS?
No — we are a private, independent publication. Coverage guidance links to official sources, and substantive revisions are dated. For official information, visit Medicare.gov or call 1-800-MEDICARE. Our disclosures →